JP2022545553A5 - - Google Patents

Info

Publication number
JP2022545553A5
JP2022545553A5 JP2022513477A JP2022513477A JP2022545553A5 JP 2022545553 A5 JP2022545553 A5 JP 2022545553A5 JP 2022513477 A JP2022513477 A JP 2022513477A JP 2022513477 A JP2022513477 A JP 2022513477A JP 2022545553 A5 JP2022545553 A5 JP 2022545553A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
antibody
treating
single dose
preventing influenza
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022513477A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022545553A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/048635 external-priority patent/WO2021041989A1/en
Publication of JP2022545553A publication Critical patent/JP2022545553A/ja
Publication of JP2022545553A5 publication Critical patent/JP2022545553A5/ja
Priority to JP2025084157A priority Critical patent/JP2025124708A/ja
Pending legal-status Critical Current

Links

JP2022513477A 2019-08-29 2020-08-28 A型インフルエンザ感染の治療のための組成物及び方法 Pending JP2022545553A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025084157A JP2025124708A (ja) 2019-08-29 2025-05-20 A型インフルエンザ感染の治療のための組成物及び方法

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962893747P 2019-08-29 2019-08-29
US62/893,747 2019-08-29
US202062993519P 2020-03-23 2020-03-23
US62/993,519 2020-03-23
US202063040966P 2020-06-18 2020-06-18
US63/040,966 2020-06-18
PCT/US2020/048635 WO2021041989A1 (en) 2019-08-29 2020-08-28 Compositions and methods for treatment of influenza a infection

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025084157A Division JP2025124708A (ja) 2019-08-29 2025-05-20 A型インフルエンザ感染の治療のための組成物及び方法

Publications (2)

Publication Number Publication Date
JP2022545553A JP2022545553A (ja) 2022-10-27
JP2022545553A5 true JP2022545553A5 (cg-RX-API-DMAC10.html) 2023-09-04

Family

ID=72473986

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022513477A Pending JP2022545553A (ja) 2019-08-29 2020-08-28 A型インフルエンザ感染の治療のための組成物及び方法
JP2025084157A Pending JP2025124708A (ja) 2019-08-29 2025-05-20 A型インフルエンザ感染の治療のための組成物及び方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025084157A Pending JP2025124708A (ja) 2019-08-29 2025-05-20 A型インフルエンザ感染の治療のための組成物及び方法

Country Status (11)

Country Link
US (1) US20220306728A1 (cg-RX-API-DMAC10.html)
EP (1) EP4021502A1 (cg-RX-API-DMAC10.html)
JP (2) JP2022545553A (cg-RX-API-DMAC10.html)
KR (1) KR20220061999A (cg-RX-API-DMAC10.html)
CN (1) CN115052630A (cg-RX-API-DMAC10.html)
AU (1) AU2020335922B2 (cg-RX-API-DMAC10.html)
BR (1) BR112022003529A2 (cg-RX-API-DMAC10.html)
CA (1) CA3148990A1 (cg-RX-API-DMAC10.html)
IL (1) IL290752B2 (cg-RX-API-DMAC10.html)
MX (1) MX2022002447A (cg-RX-API-DMAC10.html)
WO (1) WO2021041989A1 (cg-RX-API-DMAC10.html)

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
EP0604580A1 (en) 1991-09-19 1994-07-06 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
KR100797667B1 (ko) 1999-10-04 2008-01-23 메디카고 인코포레이티드 외래 유전자의 전사를 조절하는 방법
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
WO2004076677A2 (en) 2003-02-26 2004-09-10 Institute For Research In Biomedicine Monoclonal antibody production by ebv transformation of b cells
KR101616758B1 (ko) * 2007-12-26 2016-04-29 젠코어 인코포레이티드 FcRn에 대한 변경된 결합성을 갖는 Fc 변이체
ES2525346T3 (es) 2008-10-22 2014-12-22 Institute For Research In Biomedicine Métodos para producir anticuerpos a partir de células plasmáticas
US20140294812A1 (en) * 2013-03-15 2014-10-02 Xencor, Inc. Fc variants that improve fcrn binding and/or increase antibody half-life
WO2016120753A1 (en) * 2015-01-28 2016-08-04 Pfizer Inc. Stable aqueous anti- vascular endothelial growth factor (vegf) antibody formulation
JP2019502715A (ja) * 2016-01-13 2019-01-31 メディミューン,エルエルシー A型インフルエンザを治療する方法
US12304928B2 (en) * 2018-05-18 2025-05-20 Cz Biohub Sf, Llc Epitope restriction for antibody selection
WO2020221450A1 (en) * 2019-04-30 2020-11-05 Humabs Biomed Sa Antibodies and methods for treatment of influenza a infection

Similar Documents

Publication Publication Date Title
JP2505944B2 (ja) (S)―α―フルオロメチル―ヒスチジン及びそのエステルを含有するぜん息治療用医薬組成物
ES2267591T3 (es) Combinaciones farmaceuticas que comprenden un antagonista del receptor p2t y melagatran.
JPH04500070A (ja) アスピリンの新規投与方法およびアスピリンを含有する新規剤形
JP7857360B2 (ja) 疣贅の治療
JP2011529078A (ja) 自己免疫疾患を治療および予防するための方法および組成物
CN120152987A (zh) 呼吸道合胞病毒rna疫苗接种
JP7369523B2 (ja) 中等度~重度のインフルエンザの処置
US9901555B2 (en) Treatment of viral infections
US7132453B2 (en) Method of using prostacyclin to treat respiratory syncytial virus infections
EP4710930A1 (en) Anti-influenza virus composition containing xanthan gum or fucoidan
JP5811404B2 (ja) セトロンを頬側経粘膜投与するための処方物(formulation)
ES2356371T3 (es) Medicamentos terapéuticos para inducir tolerancia.
JP2003171266A (ja) キシリトールを含有する解熱性調剤
US20230201309A1 (en) Compositions for the treatment of a respiratory condition
IL312401A (en) Methods for treating Crohn's disease with a specific anti-IL23 antibody
FI3407899T3 (fi) Immunoestolääkitys toistuvia bakteeri-infektioita varten
US12414928B2 (en) Viral inactivation spray and gargling formulation
US20240299530A1 (en) Method for producing blood plasma product useful in the treatment of viral infections characterized by an uncontrolled release of proinflammatory cytokines
JPS63303931A (ja) 経鼻投与用成長ホルモン放出活性物質製剤
RU2678981C2 (ru) Композиция от бешенства, содержащая адъювант pika
WO2019202285A1 (en) Pharmaceutical compositions and associated kits and uses
JP2025024653A (ja) アデノウイルス感染又はアデノウイルス感染に伴う疾患の治療
RU2249465C1 (ru) Способ лечения и профилактики иммунодефицитных состояний и заболеваний, связанных с бактериальной или вирусной агрессией
US20230310467A1 (en) PHARMACEUTICAL COMBINATION THERAPY AND PREVENTION WITH APROTININ + REMDESIVIR OF SARS-CoV-2 AND/OR DISEASE ASSOCIATED WITH THIS INFECTION, INCLUDI COVID-19
RU2333766C2 (ru) Способы введения далбаванцина для лечения бактериальных инфекций